Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 137

Results For "2022"

1428 News Found

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
News | November 10, 2021

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021


Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
News | November 10, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021


Wockhardt PAT at Rs 33.53 cr. in Q2FY22
News | November 09, 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.


EVA Pharma to open vaccine manufacturing facility in Cairo
Supply Chain | November 09, 2021

EVA Pharma to open vaccine manufacturing facility in Cairo

The new facility will provide an important boost to vaccine capacity in Africa


Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22
News | November 09, 2021

Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22

The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Divis Labs PAT at Rs 606.46 cr. in Q2FY22
News | November 08, 2021

Divis Labs PAT at Rs 606.46 cr. in Q2FY22

Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.


Prime Therapeutics to list Semglee and Insulin Glargine
News | November 05, 2021

Prime Therapeutics to list Semglee and Insulin Glargine

Biocon Biologics and Viatris co-developed the products


U.S. FDA approves ANI’s purified cortrophin gel
Biotech | November 03, 2021

U.S. FDA approves ANI’s purified cortrophin gel

Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016


EMA encourages companies to submit type I variations by end- November
Policy | November 01, 2021

EMA encourages companies to submit type I variations by end- November

Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021


Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
News | October 29, 2021

Laurus Labs PAT at Rs 201.90 cr. in Q2FY21

Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021